Journal
FRONTIERS IN IMMUNOLOGY
Volume 13, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fimmu.2022.953546
Keywords
collagen XVII; immunosuppression; autoimmune bullous disorders; skin fragility; melanoma
Categories
Funding
- Berta-Ottenstein-Programme for Advanced Clinician Scientists, Faculty of Medicine, University of Freiburg
- German Research Foundation [SFB1160, SFB1479, 441891347, KI1795/2-1]
- clinician scientist program Excellent Clinician Scientists in Freiburg-Education for Leadership (EXCEL at the Medical Center University of Freiburg, Faculty of Medicine, University of Freiburg, Germany) - Else Kroener-Fresenius-Stiftung [EXCEL2016_Kolleg.15]
Ask authors/readers for more resources
Immune checkpoint inhibitors (ICI) can induce T-cell-mediated antitumour responses and have been approved for several tumour entities. However, they can also lead to autoimmune disorders, including bullous pemphigoid (BP). In this study, we describe a cohort of eight patients who developed BP under or shortly after ICI treatment. Half of them had a severe subtype and the median onset of ICI-BP was 10 months after ICI initiation. The disease may require treatment with rituximab for remission even after ICI discontinuation.
Immune checkpoint inhibitors (ICI) induce T-cell-mediated antitumour responses. While ICI were initially successfully applied in metastasized melanoma, they are now approved for several tumour entities. Numerous autoimmune disorders have been reported to occur as adverse events of the treatment, among them bullous pemphigoid (BP), with less than 1% of the patients experiencing ICI-induced BP. This number is higher than the estimated prevalence of autoimmune bullous diseases in the general population of Germany, which lies around 0.05%. We here describe our cohort of eight patients, who developed a bullous pemphigoid under or shortly after ICI treatment. Half of them had a severe subtype (as shown by BPDAI >57) and showed a median onset of ICI-BP after 10 months of ICI initiation. Six patients had a palmar and/or plantar involvement, while oral involvement occurred in one case. All patients had linear epidermal IgG depositions in split skin in the indirect immunofluorescence. In four out of five biopsies available for direct immunofluorescence, linear IgG and C3 depositions were detected at the basement membrane, while one patient showed linear IgM staining. Moderate to high levels of FLBP180 autoantibodies were found in seven of eight cases. The disease can still be active after ICI discontinuation, while rituximab might be required for remission. Finally, four tumour samples were stained histochemically for collagen XVII (BP180), but no enhanced expression was found.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available